Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AX Other antithrombotic agents
B01AX05 Fondaparinux
D01844 Fondaparinux sodium (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Products and Modifiers
Anticoagulants
Factor Xa Inhibitors, Indirect
Fondaparinux
D01844 Fondaparinux sodium (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
33 Blood and body fluid agents
333 Anticoagulants
3339 Others
D01844 Fondaparinux sodium (JAN/USP/INN)
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01662 Factor Xa inhibitor
D01844 Fondaparinux sodium
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Serine peptidases
Chymotrypsin family
F10a
D01844 Fondaparinux sodium (JAN/USP/INN) <JP/US>
Peptidase inhibitors
Serpin family
SERPINC1 (AT3)
D01844 Fondaparinux sodium (JAN/USP/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01844
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01844
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01844
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01844
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AF Direct factor Xa inhibitors
B01AF02 Apixaban
D03213 Apixaban (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Products and Modifiers
Anticoagulants
Factor Xa Inhibitors, Direct
Apixaban
D03213 Apixaban (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
33 Blood and body fluid agents
333 Anticoagulants
3339 Others
D03213 Apixaban (JAN/USAN/INN)
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01662 Factor Xa inhibitor
D03213 Apixaban
DG03320 Direct oral anticoagulant (DOAC)
D03213 Apixaban
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D03213 Apixaban
DG02925 CYP3A5 substrate
D03213 Apixaban
Transporter substrate
DG01665 ABCB1 substrate
D03213 Apixaban
DG01913 ABCG2 substrate
D03213 Apixaban
Drug classes [BR:br08332]
Anticoagulant
DG03320 Direct oral anticoagulant (DOAC)
D03213 Apixaban
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Serine peptidases
Chymotrypsin family
F10a
D03213 Apixaban (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03213
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03213
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03213
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03213
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D03213
Drug transporters
D03213
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AF Direct factor Xa inhibitors
B01AF01 Rivaroxaban
D07086 Rivaroxaban (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Products and Modifiers
Anticoagulants
Factor Xa Inhibitors, Direct
Rivaroxaban
D07086 Rivaroxaban (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
33 Blood and body fluid agents
333 Anticoagulants
3339 Others
D07086 Rivaroxaban (JAN/USAN/INN)
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01662 Factor Xa inhibitor
D07086 Rivaroxaban
DG03320 Direct oral anticoagulant (DOAC)
D07086 Rivaroxaban
Metabolizing enzyme substrate
DG02954 CYP2J2 substrate
D07086 Rivaroxaban
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D07086 Rivaroxaban
Transporter substrate
DG01665 ABCB1 substrate
D07086 Rivaroxaban
DG01913 ABCG2 substrate
D07086 Rivaroxaban
Drug classes [BR:br08332]
Anticoagulant
DG03320 Direct oral anticoagulant (DOAC)
D07086 Rivaroxaban
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Serine peptidases
Chymotrypsin family
F10a
D07086 Rivaroxaban (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D07086
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D07086
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D07086
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D07086
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D07086
Drug transporters
D07086
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AF Direct factor Xa inhibitors
B01AF03 Edoxaban
D09546 Edoxaban tosilate hydrate (JAN) <JP/US>
USP drug classification [BR:br08302]
Blood Products and Modifiers
Anticoagulants
Factor Xa Inhibitors, Direct
Edoxaban
D09546 Edoxaban tosilate hydrate (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
33 Blood and body fluid agents
333 Anticoagulants
3339 Others
D09546 Edoxaban tosilate hydrate (JAN)
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01662 Factor Xa inhibitor
DG01398 Edoxaban
D09546 Edoxaban tosilate hydrate
DG03320 Direct oral anticoagulant (DOAC)
DG01398 Edoxaban
D09546 Edoxaban tosilate hydrate
Transporter substrate
DG01665 ABCB1 substrate
DG01398 Edoxaban
D09546 Edoxaban tosilate hydrate
Drug classes [BR:br08332]
Anticoagulant
DG03320 Direct oral anticoagulant (DOAC)
D09546 Edoxaban tosilate hydrate
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Serine peptidases
Chymotrypsin family
F10a
D09546 Edoxaban tosilate hydrate (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09546
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09546
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09546
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09546
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D09546
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01662 Factor Xa inhibitor
DG01398 Edoxaban
DG03320 Direct oral anticoagulant (DOAC)
DG01398 Edoxaban
Transporter substrate
DG01665 ABCB1 substrate
DG01398 Edoxaban